Up 14% in a month, is the Resmed share price just getting started?

The sleep apnoea and respiratory company's shares have had a fine start to FY23.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Resmed shares have pushed higher in the new financial year
  • Healthcare has proven to be a defensive sector in these volatile times
  • In the past 12 months, the Resmed share price is down almost 6%

The ResMed Inc (ASX: RMD) share price has been a solid gainer this past month of trade, up almost 14% in that time.

The company's shares have travelled from a low of $27.63 apiece on 25 May to their current price of $32.34 a share.

Meanwhile, healthcare shares are rebounding in June-July, with the S&P/ASX 200 Health Care Index (ASX: XHJ) up 13% in a month as well. The year-to-date performances of both Resmed and the index are charted below:

TradingView Chart

Has the Resmed share price got more?

The broker Morgans is bullish on the Resmed share price and has a price target of $37.95.

In a recent note, the broker said its long-term view on the healthcare player is positive, despite market volatility.

It made note of Resmed's digital platform that addresses kinks along the "healthcare value chain" in its assessment.

Meanwhile, 64% of brokers rate Resmed as a buy right now, according to Refinitiv Eikon data. The remainder say it's a hold, with no sell ratings on the share.

The consensus price target from this list is $33.93, a fraction above its current share price.

Sector-wise, healthcare shares could catch further bids in FY23 if recent trends prevail.

Researchers at Deloitte recently noted a number of catalysts are pushing the "clinical, financial, and operational transformation" of health care – COVID-19 potentially being one of these.

Moreover, the sector is projected to deliver an average earnings per share (EPS) growth of 30% in the second half of CY2022, according to Bloomberg data.

In the past 12 months, the Resmed share price is down 5.7%, falling just over 9% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Healthcare Shares

Mesoblast shares: Q4 earnings top projections

Ryoncil® uptake has exceeded initial projections

Read more »

A woman leans forward with her hands shielding her eyes as if she is looking intently for something.
Healthcare Shares

Up 36%: Can CSL shares keep rebounding?

Find out what experts expect from CSL shares next.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Is CSL a fallen ASX giant to buy in July?

Confidence has been shaken, but I think the long-term opportunity remains attractive.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

This red-hot ASX healthcare share hit a speed bump. What next?

The tech company must convert innovation into profits to justify its lofty valuation.

Read more »

Two health workers taking a break.
Healthcare Shares

Top broker tips 37% upside for this exciting ASX healthcare stock

This healthcare stock is one to watch.

Read more »

A woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares are slipping again. Is the comeback already over?

The healthcare stock needs evidence of recovering demand before rallying further.

Read more »

A young couple sits at their kitchen table looking at documents with a laptop open in front of them.
Healthcare Shares

ResMed's $490m MatrixCare sale: What it means

ResMed announces $490 million sale of MatrixCare and future shareholder returns.

Read more »

Married elderly man and woman in love spending time together on bench on a phone, symbolising retirement.
Healthcare Shares

Summerset Group delivers Q2 update

Summerset Group saw first-half FY26 sales rise 17%, with resales up 26%.

Read more »